[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación EPIC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":546},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,39,66,91,115,141,166,194,221,242,264,286,309,330,352,381,407,430,453,473,498,522],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100612643","real-life-registry-in-patients-with-coronary-artery-disease-treated-with-the-selution-sirolimus-eluting-balloon-selution-iberia-registry-100612643",false,"NCT07256249","Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry","SELUTION","Inclusion Criteria:\n\n* Patients with age ≥18 years and;\n* Patients with coronary artery disease in whom, at the operator's discretion, treatment of a lesion in a native vessel, coronary graft or coronary restenosis is decided using the Selution SLRTM device;\n* Patient who has been informed of the characteristics of the study and has provided written informed consent.\n\nExclusion Criteria:\n\n* Express refusal of the patient to participate in the study\n* Life expectancy of the patient of less than 12 months","ALL","18 Years",{"count":19,"type":20},960,"ESTIMATED","12 Months","OBSERVATIONAL","Selution Iberia registry is a post-market clinical follow-up, prospective, multicenter, international, longitudinal, observational study without a control group of consecutive unselected \"real-world\" patients with coronary artery disease in whom it was decided to use the SELUTION SLRTM device in the treatment of primary native lesions and ISR (in-stent restenosis) in all settings, in order to evaluate its effectiveness and safety.\n\nThe primary objective is to evaluate the effectiveness and safety of the Sirolimus-eluting balloon SELUTION SLRTM based strategy in the treatment of native coronary artery stenosis and in-stent restenosis. The primary endpoint will be the incidence of major adverse cardiovascular events at 12 months, including death, non-fatal myocardial infarction or target lesion revascularization for ischemia, in an unselected \"real-world\" patient setting. Both Device Oriented Composite Endpoint (Cardiovascular death, device failure-related myocardial infarction or device failure-related ischaemia) and Patient Oriented Composite Endpoint (all cause death, any stroke, any myocardial infarction or any revascularization) will be detailed.",[25],"Cardiovascular Diseases","RECRUITING","2026-07-01",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":30},"2025-12-11",{"date":34,"type":20},"2027-01-01",{"name":36,"class":37},"Fundación EPIC","OTHER",10,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100540816","prevail-paclitaxel-coated-balloon-in-small-coronary-disease-and-high-bleeding-risk-patients-100540816","NCT06321757","PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients","PARIS","Inclusion Criteria:\n\nPatients with:\n\n* PCI with DCB on native arteries with diameters \\\u003C 3 mm.\n* Indication for PCI in acute coronary syndrome or chronic coronary syndrome or silent angina with an indication for PCI.\n\nsyndrome or silent angina with an indication for PCI.\n\n* If previous lesion preparation was required after which angiographic residual lesion should not exist with diameter stenosis \\> 30% or flow-limiting coronary dissections.\n* All antithrombotic therapies administered prior to the procedure are accepted. Still, they can be changed after the procedure.\n* Capacity to understand and sign the written informed consent.\n* If the patient has a high-bleeding risk defined by 1) PRECISE-DAPT SCORE ≥ 25 or 2) an indication for concomitant oral anticoagulation he can be included in the high- bleeding risk substudy as long as he does not meet the specific exclusion criteria.\n\nExclusion Criteria:\n\nPatients with:\n\n* Concomitant lesions on vessels \\> 3 mm in diameter in the same coronary territory.\n* PCI on in-stent restenoses.\n* PCI on culprit lesions of acute coronary syndrome with ST segment elevation.\n* Patients with an indication for PCI on additional non-culprit lesions of acute coronary syndrome with ST segment elevation may be included in the study, if only non-culprit lesions are considered for the study.\n* Life expectancy \\\u003C12 months\n* Pregnancy.\n* Participation in clinicaltrials.\n* Inability to give the written informed consent.\n* Specific exclusion criteria for the high-bleeding risk patient subgroup:\n* Past medical history of stent thrombosis.\n* Indication for dual antiplatelet therapy for a different reason.",{"count":47,"type":20},501,"5 Years","Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.",[51],"Coronary Artery Disease",[53,54,55,56],"drug-coated balloon","paclitaxel","small native vessel coronary artery disease","coronary stenoses","2026-06-23",{"date":59,"type":30},"2026-06-24",{"date":61,"type":30},"2024-02-26",{"date":63,"type":20},"2026-12-30",{"name":36,"class":37},19,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100607602","comparison-of-a-contemporary-sirolimus-eluting-stent-ihtdestiny-with-another-everolimus-eluting-stent-xience-both-with-permanent-polymers-in-patients-with-acute-coronary-syndrome-and-de-novo-coronary-artery-lesions-100607602","NCT07190690","Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions","Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)","DestinACSion","Inclusion Criteria:\n\nPatients who meet ALL inclusion criteria will be included:\n\n* Patients aged ≥18 years, and\n* Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and\n* Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and\n* Patients who have been informed of the characteristics of the study and have provided written informed consent.\n\nExclusion Criteria:\n\nPatients must not meet any of the following exclusion criteria:\n\n* Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): \"C\" (Classic Shock), \"D\" (Deteriorating) and \"E\" (Extremis).\n* Patients unable to provide informed consent.\n* Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.\n* Patients with active bleeding at the time of PCI requiring medical attention.\n* Patients with planned surgery within the next 3 months.\n* Patients with any medical condition that limits a life expectancy of less than 12 months.\n* Patients participating in another clinical trial in which the primary endpoint was not met.\n* Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.",{"count":75,"type":20},2100,"INTERVENTIONAL",[78],"NA","To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).\n\nTo compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.",[51],[82],"Drug Eluting Stents","2026-06-22",{"date":57,"type":30},{"date":86,"type":30},"2025-12-19",{"date":88,"type":20},"2030-10-15",{"name":36,"class":37},17,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100623620","long-nagomi-pmcf-study-100623620","NCT07399002","LONG NAGOMI™ PMCF STUDY","Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY","LONG NAGOMI","Inclusion Criteria:\n\n* Patients who meet ALL inclusion criteria will be included:\n* Patients aged ≥ 18 years AND;\n* Patients who according to standard practice of the hospital are amenable to PCI as indicated and considered adequate according to the European clinical practice guidelines on coronary revascularization AND;\n* Patients with at least one lesion fulfilling the \"long lesion criteria\" suitable for a single stent approach AND;\n* Patients who have been informed of the characteristics of the study and have provided written informed consent AND;\n* Intention to treat all lesions with the Ultimaster Nagomi™ stent\n\nExclusion Criteria:\n\n* Patients must not meet any of the following exclusion criteria:\n* Patients who expressly decline to participate in the study.\n* Pregnant or breastfeeding women.\n* Patients with acute coronary syndrome (ACS) under conditions of cardiogenic shock (Killip class 4).\n* Patients with contraindications or hypersensitivity to sirolimus.\n* Patients with a life expectancy of less than 2 years.\n* Patients in whom any surgery requiring general anesthesia is planned, comorbidity or indication likely necessitating the discontinuation of dual anti-platelet therapy before the recommended duration of dual anti-platelet therapy per the ESC or national guidelines.\n* Patients included in other clinical trials that did not reach the primary objective.",{"count":100,"type":20},1039,"The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \\_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.",[51,103],"Ischemic Heart Disease",[105,106],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","2026-06-19",{"date":57,"type":30},{"date":110,"type":30},"2026-02-27",{"date":112,"type":20},"2029-01-01",{"name":36,"class":37},7,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":76,"phases":124,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100566642","debscan-ivl-drug-eluting-balloon-or-drug-eluting-stent-to-treat-calcified-nodules-after-intravascular-lithotripsy-100566642","NCT06657833","DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.","DEBSCAN-IVL","Inclusion Criteria:\n\nPatients must meet all inclusion criteria:\n\n* Patients \\>18 years admitted for stable coronary artery disease or acute coronary syndromes and indication for percutaneous coronary intervention (PCI) and\n* Severe coronary lesion with calcified nodule, confirmed with intracoronary imaging (optical coherence tomography or intravascular ultrasound) and;\n* Lesion to treat in a vessel between 2.5 and 4 mm.\n\nExclusion Criteria:\n\nPatients must not meet any criteria\n\n* Inability to provide oral and written informed consent or unwillingness to come back for systematic angiographic follow-up.\n* Pregnant or breastfeeding patients.\n* Cardiogenic Shock or Cardiac arrest at the moment of the index procedure.\n* Impossibility to maintain double antiplatelet treatment during at least 1 month.\n* Life expectancy \\\u003C1 year.\n* Index lesion at left main stem.\n* Aorto-ostial lesion.\n* Target lesion previously treated with stents or DEB.\n* High thrombus burden in the target lesion (TIMI thrombus scale≥3).",{"count":123,"type":20},128,[78],"International, investigator-driven, multicenter, open-label, prospective randomized controlled trial where patients with de novo lesions due to calcified nodules (CN) were randomized to drug eluting balloon (DEB) or drug eluting stents (DES).",[51],[128,129,130,131],"Calcified Nodules","Calcified lesions","Drug eluting balloon","Drug eluting stent","2026-06-15",{"date":134,"type":30},"2026-06-16",{"date":136,"type":30},"2024-12-17",{"date":138,"type":20},"2027-10-30",{"name":36,"class":37},13,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100582426","ultrathin-strut-sirolimus-eluting-stent-with-bioabsorbable-polymer-in-patients-receiving-chronic-oral-anticoagulation-100582426","NCT06863155","Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation","ACO_FLEX","Inclusion Criteria:\n\nPatients must meet all inclusion criteria:\n\n* Patients with Signed informed consent and\n* Patients with \\>=18 years old and\n* Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and\n* Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used\n\nExclusion Criteria:\n\nPatients do not have to meet any exclusion criteria\n\n* Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.\n* Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).\n* Patients treatment for restenosis or stent thrombosis.\n* Patients presentation in cardiogenic shock or after cardiorespiratory arrest.\n* Patients with allergy to any of the components of the stent to be used.\n* Patients with impossibility for follow-up.\n* Patients with life expectancy less than 1 year.",{"count":149,"type":20},500,"Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.",[51,103],[153,154,155,156,157],"Chronic oral anticoagulation","Ultrathin-strut stent","Biodegradable polymer","High-bleeding risk","Percutaneous Coronary Intervention","2026-06-14",{"date":134,"type":30},{"date":161,"type":30},"2025-05-06",{"date":163,"type":20},"2029-03-31",{"name":36,"class":37},12,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":76,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100519907","comparison-of-allegra-vs-sapien-transcatheter-aortic-valves-in-valve-in-valve-indication-100519907","NCT06049654","Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication","Clinical Trial of the Results of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication","Inclusion Criteria:\n\nPatients meeting ALL the following criteria will be included:\n\n* Patients aged ≥ 18 years.\n* Severe haemodynamical valve deterioration of a biological aortic valve implanted surgically, including severe valve stenosis (effective aortic valve area \\\u003C 1.0 cm2) and\u002For severe valve regurgitation.\n* The patient has cardiac symptoms and\u002For deterioration of left ventricular ejection fraction attributable to the aortic valve disease.\n* Heart team decision of VIV procedure.\n* Patient is willing to return at 30 days for TTE and to be clinically contacted at 1 year.\n\nExclusion Criteria:\n\nPatients meeting, at least, 1 of the following criteria will be excluded:\n\n* Patients who openly express their refusal to participate in the study.\n* Female patients in gestational age.\n* Presence or suspicious of biological aortic valve thrombosis.\n* Known hypersensitivity or contraindication to antithrombotic therapy (or inability to be anticoagulated during the procedure), nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated.\n* Ongoing sepsis and\u002For suspicious or diagnosis of endocarditis.\n* Patients whose life expectancy is \\\u003C 1 year due to non-cardiac comorbid conditions.\n* Medical, social, or psychological conditions that preclude the subject from appropriate consent or adherence to the protocol required follow-up exams.\n* True inner diameter of the prosthetic valve \\> 27 mm.\n* Transfemoral access inadequate to accommodate an 18F sheath.\n* Patients included in other clinical trials (excluding registries).",{"count":174,"type":20},104,[78],"The VIVALL-2 study is a randomized trial to compare the self-expandable supra-annular Allegra and the balloon-expandable intra-annular Edwards transcatheter valve systems in patients with degenerated biological aortic surgical valve.",[178,179],"Aortic Valve Stenosis","Structural Valve Deterioration",[181,182,183,184,185],"Valve-In-Valve","Aortic stenosis","Aortic regurgitation","Trans-catheter aortic valve","Degenerated aortic valve","2026-06-12",{"date":132,"type":30},{"date":189,"type":30},"2024-02-01",{"date":191,"type":20},"2027-11-01",{"name":36,"class":37},11,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":76,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},"100572717","trial-of-orbital-atherectomy-versus-standard-strategy-in-calcified-bifurcation-lesions-100572717","NCT06736899","Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions","Randomized Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions","OraBil","Inclusion Criteria:\n\n* Patients over 18 years of age and\n* Patients with moderately or severely calcified bifurcation lesions (lateral vessel ≥ 2mm), candidates for PCI with coronary stent implantation, in whom there is the possibility of adequate clinical follow-up at 1 year and\n* Patients agree to participate in the study, by signing the Informed Consent.\n\nExclusion Criteria:\n\n* Patients with revascularization of the artery to be treated within 9 months prior to the index procedure.\n* Patients with contraindication for the use of Orbital Atherectomy:\n\n  * Patients in cardiogenic shock.\n  * Patients with Thrombotic lesions.\n  * Patients with Vascular graft disease.\n  * Patients with remain vessel disease.\n  * Patients with severe left ventricular dysfunction.\n  * Patients allergic to the components of the washing serum (glide).\n* Patients with life expectancy less than one year.",{"count":203,"type":20},200,[78],"Clinical research with medical devices indicated in accordance with the CE marking, led by researchers, multicenter, open, prospective, randomized and controlled. Patients are randomized to treatment with a conventional balloon and then a coronary stent or to initial plaque modification with Orbital Atherectomy (OA) and then a coronary stent. To evaluate the efficacy and safety of OA in the adequate treatment with coronary stent of the calcified bifurcation lesion using angiography and optical coherence tomography (OCT).",[51,207],"Coronary Disease",[209,157,210,211],"Orbital Atherectomy (OA)","Bifurcation","Side Branch Treatment: Mid-term results","2026-04-30",{"date":214,"type":30},"2026-05-01",{"date":216,"type":30},"2025-10-23",{"date":218,"type":20},"2026-12-31",{"name":36,"class":37},8,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":5},"100492944","coroflex-isar-neo-pmcf-study-100492944","NCT05698732","Coroflex® ISAR NEO PMCF Study","Coroflex® ISAR NEO Coronary Stent System Post-Market Clinical Follow-up Study","rEPIC07","Inclusion Criteria:\n\nCoroflex® ISAR NEO is intended to be used for\n\n* Patients must be at least 18 years of age AND\n* The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his\u002F her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND\n* Patients with Novo lesion length 2-4 mm AND\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with express refusal by the patient to participate in the study.\n* Patients pregnant women and lactating women.\n* Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4).\n* Patients in whom anti-platelet and\u002For anti-coagulation therapy is contraindicated\n* Patients with lesions, that possibly can not be treated successfully with Percutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation\n* Patients with known sensitivity to Sirolimus, the carrier Probucol, the procedural co-medication or the alloying component of the stent\n* Patients with known sensitivity to contrast agents who cannot be premedicated.\n* Patients with contraindications or hypersensitivity to sirolimus\n* Patients with a life expectancy of less than 2 years\n* Patients included in other clinical trials",{"count":230,"type":20},3000,"International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Coroflex® ISAR NEO coronary stent system sirolimus eluting stent.",[233,103],"Coronary Artery Disease (CAD)",[105,106,235],"Drug Eluting Stent",{"date":214,"type":30},{"date":238,"type":30},"2023-08-04",{"date":240,"type":20},"2027-02-01",{"name":36,"class":37},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100636510","spanish-prospective-registry-of-hydra-thv-for-transcatheter-aortic-valve-implantation-100636510","NCT07566624","Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation","HYSPANIA","Inclusion Criteria:\n\nParticipants who meet ALL of the following conditions will be included:\n\n* Age ≥ 18 years and;\n* Severe aortic stenosis with indication for aortic valve replacement in which a Hydra THV device is implanted according to the instructions for use; and\n* Signed informed consent.\n\nExclusion Criteria:\n\nPatients who do NOT meet ANY of the following conditions will be included:\n\n* Express refusal by the participant to participate in the study.\n* Aortic stenosis patients who are not candidates for Hydra THV device implantation or in whom implantation of this device is performed for an indication other than aortic stenosis (especially pure native aortic valve insufficiency). Patients in whom the Hydra THV device is implanted to treat patients with degenerated aortic bioprostheses may be included in the study.\n* Participants in randomised clinical trials who have not reached the research endpoint.\n* Pregnant and\u002For breastfeeding women.",{"count":250,"type":20},100,"This study is designed to evaluate the success rate of transfemoral implantation of the Hydra THV biological aortic valve prosthesis in patients with severe symptomatic aortic stenosis. The device is used in accordance with its Instructions for Use as a CE-marked transcatheter heart valve system.\n\nThe study will assess procedural success, device performance, and early clinical outcomes following implantation. Patients undergoing transcatheter aortic valve replacement (TAVR) via the transfemoral approach will be followed to evaluate safety and effectiveness outcomes, including short- and mid-term clinical follow-up.",[253,254,178],"Severe Aortic Valve Stenosis","Valvular Heart Disease","NOT_YET_RECRUITING","2026-04-27",{"date":258,"type":30},"2026-05-05",{"date":260,"type":20},"2026-06-01",{"date":262,"type":20},"2029-02-01",{"name":36,"class":37},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":285},"100499836","sequent-extended-study-100499836","NCT05788432","Sequent Extended Study","Sequent Please Neo Extended Post-Market Clinical Follow-up Study","rEpic06","Inclusion Criteria:\n\n* Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.\n* Informed Consent Signed.\n\nExclusion Criteria:\n\n* Patient life expectancy less than 12 months.\n* Contraindication for antiplatelet therapy.\n* Not meet inclusion criteria.",{"count":273,"type":20},2028,"Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.",[51,103],[105,106,277],"Paclitaxel eluting coronary balloon dilatation catheter","2026-04-21",{"date":280,"type":30},"2026-04-22",{"date":282,"type":30},"2023-03-28",{"date":27,"type":20},{"name":36,"class":37},27,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":76,"phases":295,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":114},"100550558","drug-releasing-ball-vs-pharmacoactive-stent-in-large-vessels-morphological-analysis-and-function-vasomotor-debora-study-in-large-vessels-morphological-analysis-and-function-vasomotor-debora-study-100550558","NCT06448637","DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)","DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)","Inclusion Criteria:\n\nPatients who meet all of the following conditions are included.\n\n* Patients aged ≥ 18 years and;\n* Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;\n* Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;\n* Patients who have been informed of the characteristics of the study and have provided their written informed consent.\n\nExclusion Criteria:\n\nPatients who meet at least one of the following conditions are excluded:\n\n* Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).\n* Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.\n* Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.\n* Patients who received a combination of DES and DCB in the same vessel\n* Patients with glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F 1.73 m2\n* Patients with body mass index \\>35 (may affect the evaluation qualitative diameter of the coronary artery).\n* Patients with symptomatic congestive heart failure.\n* Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).\n* Patients with heart transplant.\n* Patients with anemia (Hb \\\u003C12 g\u002FdL in men and \\\u003C10 g\u002FdL in women).\n* Patients, women of childbearing age with a positive pregnancy test.\n* Pregnant female patients.\n* Patients included in other clinical trials with active follow-up.",{"count":294,"type":20},94,[78],"Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm",[51],[299,300],"Drug-coated balloon","Vasomotor function","2026-03-20",{"date":303,"type":30},"2026-03-23",{"date":305,"type":30},"2024-10-23",{"date":307,"type":20},"2027-05-01",{"name":36,"class":37},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":329},"100564590","essential-pro-study--repic04e-hk--100564590","NCT06631157","Essential Pro Study ( rEPIC04E-HK )","Essential Pro Post-Market Clinical Follow-up Study","rEPIC04E-HK","Inclusion Criteria:\n\n* Patient treated with Essential Pro according to routine hospital practice and following instructions for use\n* Informed consent signed\n\nExclusion Criteria:\n\n* Not meet inclusion criteria",{"count":250,"type":20},"Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.",[51,103],[105,106,277],"2026-02-12",{"date":323,"type":30},"2026-02-17",{"date":325,"type":30},"2025-05-15",{"date":327,"type":20},"2026-11-01",{"name":36,"class":37},1,{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":76,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":351},"100537089","postprocedural-contrast-mediated-ffr-plus-intracoronary-infusion-of-nitroglycerin-in-multivessel-patients-prometeus-trial-100537089","NCT06273293","Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)","Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients","Inclusion Criteria:\n\n* Patients \\>18 years old and,\n* Patients with multivessel coronary artery disease (multivessel coronary artery disease will be considered the presence of significant stenosis in 2 or more first or second order vessels greater than 1.5 mm in diameter with an angiographic reduction of their diameter ≥50% by visual estimation) subsidiary of percutaneous coronary revascularization in at least one of them and,\n* Use of Navvus pressure microcatheter both for functional diagnosis and for post-PCI evaluation of the different vessels and,\n* Patients who have signed the Informed Consent.\n\nExclusion Criteria:\n\n* Patients with intolerance or contraindication to adenosine.\n* Hemodynamically unstable patients, acute phase of a STEACS.\n* Patient with significant comorbidity with limited life expectancy.\n* Patients with the patient's express refusal to participate in the study.\n* Pregnant or breastfeeding female patients.",{"count":338,"type":20},150,[78],"the use of pressure wires is the standar of care to evaluate angiographically intermediate coronary lesions, however, limitations in the management of these type of lesions continue to be a challenge for the interventional cardiologist. The use of FFR has some limitations such as the use of adenosine due to its cost, adverse effects (e.g. transient atrioventricular block, angina, headache, etc.), time consuming and some relative contraindications for its use. In this sense, in recent years new rest indices (iFR, RFR, dPR) and hyperemic indices without adenosine (cFFR-NTG, Pd\u002FPa-NTG or cFFR) have been developed, demonstrating an improvement in terms of outcomes with its use, so they can also be used as a tool to guide us to plan our strategy. These new indices, particularly the cFFR-NTG, are simpler, at least as safe and have an excellent correlation with the FFR with adenosine in the assessment of intermediate coronary lesions.\n\nIn recent years, functional assessment after intervention has also been increasingly implemented, which, like intracoronary imaging, can make us change our attitude and correlate with the prognosis. The lower implementation of this practice, especially in multivessel patients, may result from having to lose the position of the wire to check equalization, difficulty in crossing the wire, wear\u002Fbreakage of the material after diagnosis (2-3 vessels), use more time and contrast, etc. These problems could be reduced, at least partially, with the use of the workhorse coronary guidewire pressure microcatheter to measure post-PCI functional assessment. Although the usefulness of post-PCI FFR has been demonstrated, there is no clearly established cut-off value (0.84-0.96) and it seems that in reality the values are a continuum of risk so that the higher the value, the better the prognosis . Furthermore, other simpler indices such as rest or hyperemic indices without adenosine have not been correlated with FFR in post-PCI.\n\nThe purpose of this study is to evaluate the correlation between cFFR-NTG and other indices taking FFR as a reference in multivessel patients after undergoing intervention. Establish cut-off points and correlate it with adverse cardiovascular events (MACE) in a 1-year clinical follow-up.",[207],[343,344],"Percutaneous Coronary Intervention (PCI)","Fractional Flow Reserve",{"date":323,"type":30},{"date":347,"type":30},"2024-05-31",{"date":349,"type":20},"2027-01-20",{"name":36,"class":37},4,{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":76,"phases":362,"briefSummary":363,"conditions":364,"keywords":370,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":140},"100614975","a-prospective-multicenter-randomized-controlled-trial-to-investigate-the-value-of-coronary-ct-angiography-in-the-understanding-and-management-of-coronary-calcium-the-optimal-trial-100614975","NCT07286578","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium","Inclusion Criteria:\n\n* The subject must be at least 18 years of age and younger than 85 years old\n* Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression\\>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score\\>140.\n* All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm\n* Subject must provide written informed consent before any study-related procedure\n\nExclusion Criteria:\n\n* STEMI as the clinical presentation.\n* Uncontrolled or recurrent ventricular tachycardia.\n* Hemodynamic instability.\n* Hemodialysis or peritoneal dialysis.\n* Left main coronary artery stenosis \\> 50%\n* Atrial fibrillation, flutter, or arrhythmias during CT acquisition.\n* Previous PCI in the target vessel or CABG.\n* BMI ≥ 40 kg\u002Fm2\n* Insufficient CT quality assessed by the Core lab.\n* Comorbidity with life expectancy ≤ 2 years.\n* Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.\n* The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.\n* The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.\n* The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest\u002Fmediastinum.\n* Subject has a platelet count \\\u003C100,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3.\n* The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.\n* The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy \\\u003C2 years for any non-cardiac cause.\n* Subject is currently participating in another investigational drug or device clinical study.\n* Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n* Unable to provide written informed consent (IC).","85 Years",{"count":361,"type":20},700,[78],"The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.",[25,365,366,367,368,369,51],"Myocardial Ischemia","Heart Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases",[371,372],"IVUS","CT","2026-02-09",{"date":375,"type":30},"2026-02-10",{"date":377,"type":30},"2025-12-22",{"date":379,"type":20},"2030-01-01",{"name":36,"class":37},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":76,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":406},"100485283","treatment-of-functionally-non-significant-vulnerable-plaques-in-patients-with-multivessel-st-elevation-myocardial-infarction-the-vulnerable-trial-100485283","NCT05599061","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial","Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Randomized Trial","VULNERABLE","Inclusion Criteria:\n\n* Patients \\> 18 years.\n* Successful revascularization of the culprit lesion in patients undergoing coronary angiography due to ST-segment elevation (\\> 1mm in \\> 2 contiguous leads, new left bundle branch block, or true posterior MI with ST depression of \\>1mm in \\>2 contiguous anterior leads) in the first 72 hours of the symptom's onset.\n* Multivessel coronary disease with non-culprit lesions located in different vessels than the culprit lesion and ranging from 40 to 69% of DS (visual estimated diameter stenosis ) by visual estimate planned for FFR-guided revascularization in staged procedure (\\>24 hours and \\\u003C60 days after PCI of the culprit lesion).\n* Non-culprit lesions should be suitable for functional assessment with pressure wire and OCT catheter and should be suitable to be treated with a single 2.0 to 4.5 mm EES (everolimus-eluting stent ).\n* Subject agrees to not participate in any other clinical trial study for a period of 4 years following the inclusion in the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.\n* Known intolerance to aspirin, heparin, everolimus, contrast material.\n* Unresolved mechanical complication or cardiogenic shock at the staged procedure.\n* Non-culprit study lesions located in the left main coronary artery or in coronary vessels with prior coronary revascularization (PCI or by-pass) or with distal vessel occlusion.\n* Patients with long, bifurcated, severely angulated or severely calcified non-culprit study lesions non suitable to be treated with a single EES implantation.\n* Asthma or known history of bronchial hyper-reactivity.\n* Chronic renal dysfunction with creatinine clearance \\\u003C 45 ml\u002Fmin.\n* Severe comorbidities that in the opinion of the local investigators determine the patient's life expectancy \\\u003C 4 years.\n* Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.",{"count":390,"type":20},600,[78],"The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.",[51,207,103],[395,396,397],"Vulnerable Plaque","Optical Coherence Tomography","Fractional Flow Reserve and ST-elevation Myocardial Infarction","2026-01-27",{"date":400,"type":30},"2026-01-29",{"date":402,"type":30},"2023-01-30",{"date":404,"type":20},"2028-12-01",{"name":36,"class":37},49,{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":429},"100486709","supraflex-cruz-pmcf-study--repic05--100486709","NCT05617599","SUPRAFLEX CRUZ PMCF Study ( rEpic05 )","SUPRAFLEX CRUZPost-Market Clinical Follow-up Study","Multiflex","Inclusion Criteria:\n\n* ≥ 18 years old and;\n* Patients treated with SUPRAFLEX CRUZ according to routine hospital practice and following instructions for use\n* Patients with multivessel coronary artery disease (understood as that which affects more than one territory of the major epicardial coronary arteries - anterior descending, circumflex, right coronary artery) who is treated with more than 1 stent under study in lesions located in more than 1 of the aforementioned arteries.\n* Substudy: Patients with Ejection Fraction \\\u003C45% by Echocardiography\n* Informed consent signed\n\nExclusion Criteria:\n\n* Not meet inclusion criteria\n* Contraindication for antiplatelet treatment\n* Patient life expectancy less than 12 months",{"count":416,"type":20},508,"Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).",[233,103],[420,106],"CE-MDR (Medical Device Regulations)","2025-12-15",{"date":423,"type":30},"2025-12-16",{"date":425,"type":30},"2023-05-10",{"date":427,"type":20},"2026-12-01",{"name":36,"class":37},21,{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":76,"phases":440,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":329},"100564636","influence-of-vessel-wall-calcification-on-early-stent-strut-healing-100564636","NCT06631755","Influence of Vessel Wall Calcification on Early Stent Strut Healing","Influence of Vessel Wall Calcification on Early Stent Strut Healing (CaOCT Study)","CaOCT","Inclusion Criteria:\n\nPatients who meet all the following conditions will be included:\n\n* Patients aged ≥ 18 years old and;\n* Patients with clinical indication for stent implantation and;\n* Patients with OCT evaluation that shows the presence of calcified tissue underlying the lumen surface, fulfilling the definition of superficial calcium (The distance from the abluminal point of the calcium to the luminal surface is less than 500 μm, in a perpendicular axis to the vessel luminal surface. When referred to the stent struts it will be assumed that such distance of less than 500 μm will be measured between the centre of the abluminal surface of the strut and the abluminal point of the calcium, in the same perpendicular axis).and;\n* Patients with good quality baseline OCT evaluation as judged by the investigators and;\n* Patients who have been briefed on the study characteristics and have given their prior written informed consent.\n\nExclusion Criteria:\n\n* Patients who meet, at least, 1 of the following conditions will be excluded:\n* Patients with current ST-elevation Myocardial Infarction (STEMI).\n* Patients with non-native lesion: stent restenosis, segment previously treated with drug eluting balloon, arterial or saphenous vein grafts.\n* Patients with contraindication for the 1-month follow-up angiography and OCT:\n\n  * Glomerular Filtration Rate (GFR)\\\u003C 30 ml\u002Fmin\u002F1.72m2\n  * Contrast allergy\n  * Baseline post-stent control OCT failure, due to tortuosity or any other reason.\n* Patient not candidate for a follow up angiography, due to frailty, non-cardiac disease or whatever other condition considered by the local team.",{"count":439,"type":20},40,[78],"To assess the influence of superficial calcium on the early endothelialization (1 month) of the struts of the Xience Skypoint stent (comparing struts with underlying superficial calcium to struts without underlying calcification)",[51],[444,445,446],"Calcification","Strut coverage","Optical Coherence Tomography (OCT)","2025-12-12",{"date":86,"type":30},{"date":450,"type":30},"2024-11-07",{"date":214,"type":20},{"name":36,"class":37},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":76,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":4},"100612968","comparison-of-the-amplatzer-amulet-versus-lambre-device-for-left-atrial-appendage-closure-100612968","NCT07260474","Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure","Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure: the CALAMBRE Randomized Clinical Trial","CALAMBRE","Inclusion Criteria:\n\n(MUST MEET ALL INCLUSION CRITERIA)\n\n* Patient with aged ≥18 years AND;\n* Patient have non-valvular atrial (NVAF) with a CHA2DS2-VASc score ≥2, and presented at least one high-bleeding-risk criterion according to the Munich consensus document AND;\n* Patient are required to undergo preprocedural TEE \u002F CCTA to confirm the absence of LAA thrombus and to ensure that LAA anatomy is suitable for closure with either device.\n* Patient who has been informed of the characteristics of the study and has provided written informed consent..\n\nExclusion Criteria:\n\n(MUST NOT MEET ANY EXCLUSION CRITERIA)\n\n* Patient life expectancy \\\u003C1 year (terminal illness).\n* Patient with requirement for oral anticoagulation therapy for any indication other than non-valvular atrial fibrillation.\n* Patient with prior surgical ligation or obliteration of the left atrial appendage.\n* Patient with history of allergic reaction or intolerance to any material used in the study devices or to any of the antithrombotic agents required post-procedure.\n* Patient with active systemic infection.\n* Patient with concurrent participation in another investigational study that may affect study results.\n* Patient with inability or unwillingness to comply with the study protocol or follow-up requirements.\n* Patient pregnant or breastfeeding women.",{"count":203,"type":20},[78],"Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.",[51],"2025-11-21",{"date":467,"type":30},"2025-12-03",{"date":469,"type":20},"2026-01-30",{"date":471,"type":20},"2027-01-31",{"name":36,"class":37},{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":76,"phases":483,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":329},"100441626","phase-4-cross-over-study-of-coronary-risk-factors-with-a-polypill-100441626","NCT05030818","Cross-over Study of Coronary Risk Factors With a Polypill","Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill","POLICROSS","Inclusion Criteria:\n\nPatients over 18 years of age. Patients under treatment with the Trinomia® polypill in any of its presentations for indication of secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent.\n\nExclusion Criteria:\n\nPatients who do not sign the informed consent. Patients with an inability to understand and comply with the protocol. Patients with contraindication to any component of the polypill. Patients who are already participating in another clinical trial. Patients with any condition that limits life expectancy to \\\u003C1 year. Patients with programmed coronary revascularization. Patients with coronary stent implantation in the last 12 months. Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is, low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.",{"count":482,"type":20},88,[484],"PHASE4","Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.",[51],[488,489,490],"Hypertension","LDL-cholesterol","Platelet inhibition","2025-08-04",{"date":493,"type":30},"2025-08-05",{"date":495,"type":30},"2022-10-14",{"date":212,"type":20},{"name":36,"class":37},{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":76,"phases":507,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":351},"100510723","results-of-the-use-of-two-stentrievers-simultaneosly-compared-with-one-as-a-primary-treatment-in-acute-ischemic-stroke-100510723","NCT05930145","Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke","A Randomized Study Comparing the Effectiveness and Security of the Use of Two Stentrievers Simultaneously Versus One Stentriever as a Primary Treatment in Acute Ischemic Stroke Patients.","DIVERSO","Inclusion Criteria:\n\n* A new disabling focal neurological deficit compatible with acute cerebral ischemia.\n* Any age. Informed consent obtained from the patient or representative.\n* NIHSS score ≥ 6.\n* Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale.\n* Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography).\n* ASPECTs score on baseline CT greater than or equal to 6.\n* In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center.\n\nExclusion Criteria:\n\n* Those described in the usual protocols for mechanical thrombectomy of each hospital.\n* Pre-existing functional clinical status greater than 2 according to the mRS clinical scale\n* Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery.\n* Initiation of treatment with a different technique than the one described.\n* Inability to use a proximal balloon guide catheter.\n* Use of aspiration catheter.\n* Intracranial atherosclerotic plaque as the cause of occlusion.\n* Advanced or terminal disease with a life expectancy of less than 6 months.\n* Patient who is participating in another study that may affect this one.\n* ASPECTS score less than or equal to 6 on baseline CT.\n* Evidence of significant hemorrhage or mass effect with midline shift on baseline CT.\n* Patients with occlusions in multiple vascular territories.\n* Evidence of intracranial tumor (except for small meningiomas)",{"count":203,"type":20},[78],"Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c\u002F3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.",[510,511,368],"Stroke","Thrombectomy",[510,513,511],"Double Stentriever","2025-07-24",{"date":516,"type":30},"2025-07-28",{"date":518,"type":30},"2025-03-14",{"date":520,"type":20},"2026-10-01",{"name":36,"class":37},{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":5},"100563791","safety-and-effectiveness-of-short-term-single-antiplatelet-therapy-after-left-atrial-appendage-closure-with-the-lambre-device-in-patients-with-nonvalvular-atrial-fibrillation-a-multinational-real-world-registry-100563791","NCT06620757","Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry","S-SAPT LAMBRE","Inclusion Criteria:\n\nAll criteria must be met\n\n* Patient 18 years and over and\n* Patient with documented nonvalvular AF, defined as AF in the absence of moderate or severe mitral stenosis or a mechanical heart valve and\n* Patient with a calculated CHA₂DS₂-VASc score ≥2 (for men) and ≥3 (for women) and\n* Patient with a contraindication for long-term anticoagulant treatment and\n* Patient who has undergone a successful LAmbre LAAC device implantation with no complications during the in-hospital period after the intervention and\n* Patient able and willing to return for required follow-up visits and examinations and\n* Patient with Informed consent signed.\n\nExclusion Criteria:\n\nNo exclusion criteria must be met.\n\n* Patient is currently enrolled in another investigational study, except when the subject is participating in a purely observational registry with no associated treatments.\n* Patient requires long-term anticoagulation therapy for reasons other than AFrelated stroke risk reduction, for example, due to an underlying hypercoagulable state (i.e even if the device is implanted, the subjects would not be eligible to discontinue OAC (Oral Anticoagulation) due to other medical conditions requiring chronic OAC therapy).\n* Patient has contraindications or is allergic to both aspirin and clopidogrel.\n* Patient has an indication for chronic aspirin or clopidogrel treatment (i.e., chronic ischemic disease or peripheral artery disease); thus, the subject would not be eligible to discontinue aspirin or clopidogrel due to other medical conditions requiring this therapy.\n* Patient had or is planning to have any cardiac or noncardiac intervention or surgical procedure within 30 days before or 60 days after implant (including, but not limited to: cardioversion, PCI (Percutaneous Coronary Intervention), cardiac ablation, cataract surgery, etc.).\n* Patient had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment.\n* Patient had a major bleeding event within the 30 days prior to inclusion. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding\u002Fbleeding source are further exclusions, regardless of the timing of the bleeding event.\n* Patient has an active bleeding.\n* Patient has had an MI documented in the clinical record as either a NSTEMI or STEMI, with or without intervention, within 30 days prior to enrollment.\n* Patient has a history of atrial septal repair or has an ASD\u002FPFO device.\n* Patient is of childbearing potential, or plans to become pregnant during the study (method of assessment upon study physician's discretion).\n* Patient had subject has a documented life expectancy of less than one year.","100 Years",{"count":531,"type":20},234,"Brief Summary: A prospective, multicenter, single-arm, non-randomized study including consecutive patients with nonvalvular AF(Atrial Fibrillation), with a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), and contraindication for long-term anticoagulant treatment, with successful LAAC (Left Atrial Appendage Closure)procedure with the LAmbre device, who at discharge are eligible for short-term (3-months-only) SAPT. We want to assess if a short-term single antiplatelet therapeutic regime of Acetylsalicylic acid (ASA) 100 mg (or clopidogrel 75 mg if ASA contraindication), once daily, for 3 months is safe and effective at 12 months follow-up.",[534],"Atrial Fibrillation",[536,537],"Left Atrial Appendage Closure","Single Antiplatelet Therapy","2025-07-03",{"date":540,"type":30},"2025-07-04",{"date":542,"type":30},"2024-10-10",{"date":544,"type":20},"2027-10-01",{"name":36,"class":37},""]